(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 July 2015 (09.07.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/102400 A1

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61K 47/38* (2006.01)
A61K 9/48 (2006.01) *A61K 31/505* (2006.01)
A61K 9/20 (2006.01)

(21) International Application Number:
PCT/KR2014/013087

(22) International Filing Date:
30 December 2014 (30.12.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2013-0167156
30 December 2013 (30.12.2013) KR
10-2014-0071081 11 June 2014 (11.06.2014) KR

(71) Applicant: **HANMI PHARM. CO., LTD.** [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-958 (KR).


(72) Inventors: **CHO, Jung Hyun**; 522-1706, 34, Cheoncheon-ro 22beon-gil, Jangan-gu, Suwon-si, Gyeonggi-do 440-841 (KR). **KIM, Jin Cheul**; 506-401, 16, Dangsan-ro 42-gil, Yeongdeungpo-gu, Seoul 150-754 (KR). **KIM, Yong Il**; 147-2201, 57, Hwasan-ro, Paldal-gu, Suwon-si, Gyeonggi-do 442-872 (KR). **LEE, Seung Jun**; 216-1902, 299, Sanbon-ro, Gunpo-si, Gyeonggi-do 435-765 (KR). **PARK, Jae Hyun**; 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-809 (KR). **WOO, Jong Soo**; 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR).

(74) Agent: **Y.P.LEE, MOCK & PARTNERS**; 12F Daelim Acrotel, 13 Eonju-ro 30-gil, Gangnam-gu, Seoul 135-971 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ,

[Continued on next page]

(54) Title: COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN



(57) Abstract: Provided are a solid composite formulation for oral administration, the solid composite formulation including: an ezetimibe granules-part including ezetimibe, said ezetimibe having a particle size distribution wherein the average particle size $d_{(0.9)}$ for the bottom 90% is about 10 μm or less; and a rosuvastatin mixture-part including rosuvastatin or a pharmaceutically acceptable salt thereof, and a method of preparing the composite formulation.

WO 2015/102400 A1

LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*